Company Experiences Positive Sales Impact From Recent Brazil Clearance

SALT LAKE CITY,Â Feb. 23, 2016-Â Amedica CorporationÂ (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce its participation in the 2016Â Brazilian Spine CongressÂ occurringÂ March 3-4, 2016Â inÂ Sao Paulo, Brazil.

"Brazil has been an emerging growth opportunity for us since achieving clearance during the third quarter of last year thanks in part to our Brazilian partner, Sintex Medical," said Dr.Â Sonny Bal, Chairman and Chief Executive Officer. "We feel that the content we plan to present, and the surgeons with whom we will be meeting inÂ Sao PauloÂ will strengthen this additional sales channel through the balance of this year."

"With the limited options currently available to Brazilian surgeons,Â BrazilÂ reflects a market opportunity for new technologies in spinal products and surgical techniques," said Daniel Bolotnicki, Chief Executive Officer of Sintex Medical. "We've experienced very positive feedback with the silicon nitride fusion devices since our initial launch last quarter, due in part to the unique osteoconductive, anti-infective, and superior imaging properties of silicon nitride. We anticipate further geographic expansion, and expect to capture a significant share of the market from legacy PEEK cages that have inherent limitations. We are confident the Brazilian market will understand the superiority of silicon nitride, in terms of positively affecting patient outcomes."

"I look forward to presenting and sharing the clinical outcomes I've experienced while using silicon nitride the past several years," said Dr.Â Graham C. Calvert, M.D., Mississippi Sports

Medicine and Orthopedic Center. "Silicon nitride truly is a breakthrough material and contains a unique surface biochemistry which ensures reliable osseointegration, while also inhibiting bacterial biofilm adhesion."

The 16th annualÂ Brazilian Spine CongressÂ attracts leading clinicians, surgeons, and scientists from theÂ AmericasÂ who come together to present the latest innovative musculoskeletal clinical and scientific research. For more information on theÂ Brazilian Spine Congress, please visitÂ http://cirurgiaespinhal.com.br/2016/ .

AboutÂ Amedica Corporation

AmedicaÂ is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic.Â AmedicaÂ markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company's products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers.Â Amedica'sÂ spine products areÂ FDA-cleared, CE-marked, and are currently marketed in theÂ U.S.Â and select markets inÂ EuropeÂ andÂ South AmericaÂ through its distributor network and its growing OEM and private label partnerships.

For more information onÂ AmedicaÂ or its silicon nitride material platform, please visitÂ www.amedica.com

.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include, but are not limited to, the intent, belief or current expectations of AmedicaÂ and members of its management team with respect toÂ Amedica'sÂ future performance, business operations and acceptance of its technology platform. Statements relating toAmedica'sÂ market opportunities, growth, future products, market acceptance of its products, sales and financial results and similar statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use ofÂ Amedica'sÂ products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press

release can also be found inÂ Amedica'sÂ Risk Factors disclosure in its Annual Report on Form 10-K, filed with theÂ Securities and Exchange CommissionÂ (SEC) onÂ March 24, 2015, and inÂ Amedica'sÂ other filings with theÂ SEC.Â AmedicaÂ disclaims any obligation to update any forward-looking statements.